Hansa Biopharma (Q4 initial take): Strong European Sales Beats Forecast - Redeye

Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat of our estimate. IDEFIRIX sales amounted to SEK61m. We expect a positive share price reaction.

Länk till analysen i sin helhet: https://www.redeye.se/research/1148656/hansa-biopharma-q4-initial-take-strong-european-sales-beats-forecast?utm_source=finwire&utm_medium=RSS